Neurocrine biosciences to present wide-ranging one-year data from phase 3 cahtalyst™ pediatric study at pediatric endocrine society 2025 annual meeting

One-year data show lasting reductions in glucocorticoid doses and improvements in clinical outcomes with crenessity™ (crinecerfont) in pediatric patients with classic congenital adrenal hyperplasia san diego , may 16, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced it will present new data from the phase 3 cahtalyst™ pediatric study showing lasting reductions in glucocorticoid doses in pediatric patients with classic congenital adrenal hyperplasia who received crenessity™ (crinecerfont) for up to one year. in addition, the study showed that for patients on crenessity, adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained below baseline levels, despite substantially decreased glucocorticoid doses.
NBIX Ratings Summary
NBIX Quant Ranking